April 22nd 2024
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Expert Highlights Responses Seen With Ibrutinib Plus CAR T-Cell Therapy Combination in CLL
January 10th 2019Jordan Gauthier, MD, MSc, discussed the results presented at the 2018 ASH Annual for this clinical trial and where the research is headed for patients with CLL. He also highlights another promising combination for this patient population that was presented at the meeting as well.
Read More
Individualized-Dose Lenalidomide-Based Regimen a Possible Frontline Treatment for Advanced CLL
January 10th 2019A triplet regimen consisting of chlorambucil and rituximab in combination with an individualized dose of lenalidomide can potentially be used as a frontline treatment for patients with advanced chronic lymphocytic leukemia who are older or unfit for standard treatment with fludarabine, cyclophosphamide, and rituximab.
Read More
Dasatinib Receives FDA Approval for Pediatric Ph+ ALL
January 3rd 2019Dasatinib (Sprycel) tablets has been approved by the FDA to be used in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.<br />
Read More
Quantifying the Benefits of Precision Oncology
December 14th 2018Precision medicine has produced some dramatic successes in patients with advanced cancer. With developments in molecular profiling, targeted therapies are being applied to multiple tumors, most notably in advanced melanoma, NSCLC, and several types of leukemia. Alison Schram, MD, and David M. Hyman, MD, point out the challenges in determining the proportion of patients who will benefit from receiving targeted therapies.
Read More
High MRD-Negative Status Seen With Venetoclax Plus Rituximab Combination in CLL
December 13th 2018The combination of venetoclax with rituximab led to high rates of undetectable minimal residual disease for patients with relapsed/refractory chronic lymphoblastic leukemia. This was associated with a prolonged progression-free survival, according to a new analysis of a randomized trial presented at the 2018 ASH Annual Meeting.
Read More
Acalabrutinib Demonstrates Promising Response Rates in CLL
December 13th 2018The BTK inhibitor acalabrutinib demonstrated promising reponse rates in patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia, according to results from an open-label phase II trial.
Read More
Wierda Compares Treatment Options for Patients With CLL
December 11th 2018During a recent <em>Targeted Oncology </em>case-based peer perspective presentation, William G. Wierda, MD, PhD, revealed the treatment options and decisions he makes when treating patients with chronic lymphocytic leukemia. Wierda explained his treatment decisions based on a patient’s case scenario.
Read More
Hematology Experts Weigh In on Top Abstracts at 2018 ASH Annual Meeting
December 6th 2018Although there were a variety of encouraging data presented at the 2018 ASH Annual Meeting, CLL and multiple myeloma undoubtedly ruled the day, according to poll results. As these topics heated up on Twitter, a few experts took a moment to discuss their thoughts on some of the top abstracts that were presented.
Read More
Single-Agent Venetoclax Leads to High MRD Rates in Relapsed/Refractory CLL
December 5th 2018Venetoclax monotherapy induced high rates of minimal residual disease in the peripheral blood and bone marrow in patients with relapsed/refractory chronic lymphoblastic leukemia in a pooled analysis of 2 clinical trials. Data from the analysis was reported during the poster session at the 2018 ASH Annual Meeting.
Read More
I-O Combo of Checkpoint Inhibitor With CAR T-Cell Therapy Shows Promise in Relapsed B-Cell ALL
December 3rd 2018According to results from a small clinical study, checkpoint inhibitors in combination with chimeric antigen receptor T-cell therapy showed promise for improving CAR T-cell persistance in some patients with relapsed B-cell acute lymphoblastic leukemia. <br />
Read More
Risk of Relapse Reduced With HCT Following CAR T-Cell Therapy in ALL
December 2nd 2018Patients with acute lymphoblastic leukemia saw a reduction in the risk for recurrence after receiving a stem cell transplant for the first time following treatment with CD19 chimeric antigen receptor T-cell therapy.
Read More
Tisagenlecleucel Sustains Relapse-Free Survival, Overall Survival in Pediatric R/R ALL
December 2nd 2018According to updated data from the phase II ELIANA study, CD19-targeted CAR T-cell therapy tisagenlecleucel as treatment of pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia sustained rates of relapse-free survival and overall survival at 24 and 18 months.
Read More
FDA Grants Priority Review Designation to Quizartinib for FLT3-ITD+ AML
November 26th 2018A new drug application for quizartinib has been granted a priority review by the FDA for the treatment of adult patients with relapsed/refractory <em>FLT3</em>-ITD–positive acute myeloid leukemia. The designation is based on findings from the phase III QuANTUM-R study.
Read More
Glasdegib Granted FDA Approval for AML
November 21st 2018Glasdegib (Daurismo) has been granted FDA approval for combination use with low-dose cytarabine for the treatment of patients with newly-diagnosed acute myeloid leukemia who are aged 75 years or older or who are ineligible for intensive chemotherapy.
Read More
Frontline Venetoclax Granted Accelerated FDA Approval for Older Patients With AML
November 21st 2018Venetoclax (Venclexta) has been granted an accelerated approval by the FDA for combined use with azacitidine or decitabine or low-dose cytarabine as a treatment for adult patients with newly-diagnosed acute myeloid leukemia who are aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Read More
Diagnosis, Risk Stratification, and Prognosis in Patients With Chronic Lymphocytic Leukemia
November 13th 2018Chronic lymphocytic leukemia is characterized by the clonal proliferation and accumulation of small, mature-appearing CD5-positive B lymphocytes in the blood, bone marrow, and secondary lymphoid tissues. A CLL diagnosis is established by the presence of more than 5x109/L peripheral lymphocytes co-expressing CD5, CD19, and CD23, and weakly expressing CD20, CD79b, and surface immunoglobulin. Small lymphocytic lymphoma represents a clinical variant of CLL and is similarly managed.
Read More
A Look Back at FDA News from October 2018
November 1st 2018A look back at all the FDA news that happened in the month of October 2018, including several new FDA approvals, priority reviews, a breakthrough therapy designation, and more, in a variety of cancer types.<br />
Read More
PFS Improvement With Venetoclax Plus Obinutuzumab in Frontline CLL
November 1st 2018Treatment-naïve patients with chronic lymphocytic leukemia who had comorbidities saw a reduction in the risk of disease progression or death after treatment with venetoclax combined with obinutuzumab versus obinutuzumab plus chlorambucil.
Read More
Ibrutinib and Obinutuzumab Combo Granted Priority Review by FDA For Frontline CLL
October 17th 2018A supplemental new drug application for ibrutinib (Imbruvica) has been granted a priority review by the FDA for use in combination with obinutuzumab (Gazyva) as a frontline treatment for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More